ORPHA:95699
Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency
Also known as: Congenital adrenal hyperplasia due to cytochrome POR deficiency · POR deficiency · PORD
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
240
73.8th percentile
Trials
0
Interventional, condition-specific
Researchers
993
Distinct authors in sample
Gene link
POR
Strong
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare form of adrenal hyperplasia due to P450 oxidoreductase deficiency and characterized by glucocorticoid deficiency, virilization of external genitalia in females, and undervirilization in males. Findings range from severely affected infants with 46,XX and 46,XY disorders/differences of sex development (DSD) and cortisol deficiency to mildly affected women who appear to have polycystic ovary syndrome, or mildly affected men with gonadal insufficiency.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0013310
- OMIM:613571
- UMLS:C1860042
- NCIT:C174439
Additional Mondo synonyms (1)
congenital adrenal hyperplasia due to cytochrome POR deficiency
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedPresent
Strong — POR
- LiteraturePresent
240 matched papers (149 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 47 for broader category congenital adrenal hyperplasia
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (POR).
GenCC classification: Strong.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
240
240 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
240 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
149 in the last 10 years · medium confidence · 73.8th percentile (publications denominator)
Phrase hits: 240 · MeSH hits: 0
Who's working on it?
993
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Pandey AV25 papers · 2026
Division of Pediatric Endocrinology, Department of Pediatrics, University Children's Hospital Bern Bern, Switzerland ; Program in Molecular Life Sciences, Department of Biology, University of Bern Bern, Switzerland.
Papers in Europe PMC - 02Miller WL20 papers · 2025
Department of Pediatrics, University of California, San Francisco, San Francisco, California 94143-0978, USA. wlmlab@ucsf.edu
Papers in Europe PMC - 03Flück CE17 papers · 2025
Pediatric Endocrinology and Diabetology, University Children’s Hospital Bern, Bern, Switzerland
Papers in Europe PMC - 04Arlt W16 papers · 2025
Centre for Endocrinology, Diabetes and Metabolism, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, UK
Papers in Europe PMC - 05Huang N9 papers · 2011
Department of Pediatrics, University of California, San Francisco, San Francisco, CA 94143-0978, USA.
Papers in Europe PMC - 06Ogata T8 papers · 2026
Department of Endocrinology and Metabolism, National Research Institute for Child Health and Development, Tokyo, Japan
Papers in Europe PMC - 07Agrawal V7 papers · 2011Papers in Europe PMC
- 08Auchus RJ7 papers · 2022
Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine and Department of Pharmacology, University of Michigan, Rm. 5560A MSRBII, 1150 W Medical Center Drive, Ann Arbor, MI 48109, United States. Electronic address: rauchus@med.umich.edu.
Papers in Europe PMC - 09Fukami M6 papers · 2018
Department of Endocrinology and Metabolism, National Research Institute for Child Health and Development, Tokyo, Japan.
Papers in Europe PMC - 10Idkowiak J6 papers · 2025
Centre for Endocrinology, Diabetes, and Metabolism, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham B15 2TT, United Kingdom.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 47 trials are registered for congenital adrenal hyperplasia, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
medium confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
47 interventional trials matched congenital adrenal hyperplasia, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: congenital adrenal hyperplasia
47
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT04252001·NOT YET RECRUITING·Growing up With the Young Endocrine Support System (YESS!)
Conditions: Congenital Adrenal Hyperplasia · Hypogonadotropic Hypogonadism · Growth Hormone Deficiency · Combined Pituitary Hormone Deficiency·Matched via name phrase
- NCT06712823·RECRUITING·An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia
Conditions: Congenital Adrenal Hyperplasia · Classic Congenital Adrenal Hyperplasia·Matched via name phrase
- NCT05669950·RECRUITING·A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
Conditions: Congenital Adrenal Hyperplasia·Matched via name phrase
- NCT07159841·RECRUITING·A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
Conditions: Congenital Adrenal Hyperplasia · Classic Congenital Adrenal Hyperplasia·Matched via name phrase
- NCT03760835·RECRUITING·Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment
Conditions: Congenital Adrenal Hyperplasia·Matched via name phrase
- NCT07536269·NOT YET RECRUITING·Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
Conditions: Congenital Adrenal Hyperplasia·Matched via name phrase
- NCT07144163·RECRUITING·A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
Conditions: Congenital Adrenal Hyperplasia · Classic Congenital Adrenal Hyperplasia·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26Likely covered — the policy lists Congenital adrenal hyperplasia as a category (Group 2), and this condition is a form of it. Confirm eligibility with a Centre of Excellence.
Group 2 — long-term / lifelong lower-cost interventions
NPRD envisages State Government support for dietary formulae, hormones, and other lower-cost interventions. This is a different route from the central CoE ₹50 lakh pathway; ask your state health department and a CoE which channel applies.
Central CoE funding may also apply depending on current rules — confirm with a notified Centre of Excellence. Do not assume the ₹50 lakh ceiling covers Group 2 by default. Verify
Centres of Excellence (15)
- All India Institute of Medical Sciences (AIIMS) — New Delhi, Delhi
- Maulana Azad Medical College — New Delhi, Delhi
- Sanjay Gandhi Post Graduate Institute of Medical Sciences — Lucknow, Uttar Pradesh
- Post Graduate Institute of Medical Education and Research (PGIMER) — Chandigarh, Chandigarh
- Centre for DNA Fingerprinting & Diagnostics with Nizam’s Institute of Medical Sciences — Hyderabad, Telangana
- King Edward Memorial Hospital — Mumbai, Maharashtra
- Institute of Post-Graduate Medical Education and Research (IPGMER) — Kolkata, West Bengal
- Centre for Human Genetics with Indira Gandhi Hospital — Bengaluru, Karnataka
- Institute of Child Health and Hospital for Children (ICH & HC) — Chennai, Tamil Nadu
- All India Institute of Medical Sciences (AIIMS) — Jodhpur, Rajasthan
- Sree Avittam Thirunal Hospital (SAT), Government Medical College — Thiruvananthapuram, Kerala
- All India Institute of Medical Sciences (AIIMS) — Bhopal, Madhya Pradesh
- Regional Institute of Medical Sciences (RIMS) — Imphal, Manipur
- All India Institute of Medical Sciences (AIIMS) — Patna, Bihar
- Assam Medical College & Hospital — Dibrugarh, Assam
Voluntary contributions / crowdfunding (separate from CoE funding): https://rarediseases.mohfw.gov.in/
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency" OR "Congenital adrenal hyperplasia due to cytochrome POR deficiency" OR "POR deficiency"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Congenital adrenal hyperplasia due to cytochrome P450 oxidoreductase deficiency" OR "Congenital adrenal hyperplasia due to cytochrome POR deficiency" OR "POR deficiency" OR "POR" OR "chronic primary adrenal insufficiency"
Recall-expansion terms: POR, chronic primary adrenal insufficiency
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"congenital adrenal hyperplasia"
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: PORD
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T04:47:54.984Z
